Showing results (141-150 of 153) with videos related to

Sort By:
Pageof 16
Infectious Diseases and Therapy|June 12, 2026
Real-World Data on the Use of Intravenous Fosfomycin for the Treatment of Central Nervous System Infections: a Subgroup Analysis from the FORTRESS StudyDominik Jarczak, Stefan Kluge, Martin Kieninger, et al.
Nature Neuroscience|December 3, 2024
Applying single-cell and single-nucleus genomics to studies of cellular heterogeneity and cell fate transitions in the nervous systemIgor Adameyko, Trygve Bakken, Aparna Bhaduri, et al.
Infectious Diseases and Therapy|March 19, 2025
Real-World Use, Effectiveness, and Safety of Intravenous Fosfomycin: The FORTRESS StudyKlaus-Friedrich Bodmann, Stefan Hagel, Alessandra Oliva, et al.
Disease Models & Mechanisms|November 19, 2021
A scalable, clinically severe pig model for Duchenne muscular dystrophyMichael Stirm, Lina Marie Fonteyne, Bachuki Shashikadze, et al.
Nature Cancer|January 6, 2026
De novo H3.3K27M-altered diffuse midline glioma in human brainstem organoids to dissect GD2 CAR T cell functionNils Bessler, Amber K L Wezenaar, Hendrikus C R Ariese, et al.
Bioanalysis|June 22, 2026
Vaccine Ligand Binding Assay Life Cycle Management, Assay Maintenance, Monitoring and TransferJeroen Stoop, James Huleatt, Luc Gagnon, et al.
Bioanalysis|November 14, 2024
Harmonization of Vaccine Ligand Binding Assays ValidationFrancis Dessy, Ivo Sonderegger, Leslie Wagner, et al.
Bioanalysis|February 23, 2024
2023 White Paper on Recent Issues in Bioanalysis: ISR for ADA Assays, the Rise of dPCR vs qPCR, International Reference Standards for Vaccine Assays, Anti-AAV TAb Post-Dose Assessment, NanoString Validation, ELISpot as Gold Standard (Part 3 - Recommendations on Gene Therapy, Cell Therapy, Vaccines Immunogenicity & Technologies; Biotherapeutics Immunogenicity & Risk Assessment; ADA/NAb Assay/Reporting Harmonization)Johanna Mora, Rachel Palmer, Leslie Wagner, et al.
Bioanalysis|January 25, 2025
2024 White Paper on Recent Issues in Bioanalysis: Evolution of Immunogenicity Assessment beyond ADA/NAb; Regulated Genomic/NGS Assays; Hypersensitivity Reactions; Minimum Noise Reduction; False Positive Range; Modernized Vaccine Approaches; NAb/TAb Correlation (PART 3A - Recommendations on Advanced Strategies for Molecular Assays and Immunogenicity of Gene Therapy, Cell Therapy, Vaccine; Biotherapeutics Immunogenicity Assessment & Clinical Relevance PART 3B - Regulatory Agencies' Input on Immunogenicity/Technologies of Biotherapeutics, Gene, Cell & Vaccine Therapies)Omar Tounekti, Sandra Prior, Sarah Wassmer, et al.
Bioanalysis|January 6, 2026
2025 White Paper on Recent Issues in Bioanalysis: Redosing Patients with AAV Gene Therapy; CRS Immunogenicity Risk; Shedding Assays; NHP Studies Immunogenicity; CMC vs Bioanalytical Assays; Artificial Intelligence-Powered Genomic Pipelines for NGS (PART 3A - Recommendations on Gene, Cell, and Vaccine Therapies Immunogenicity & Technologies; Biotherapeutics & Biosimilars Immunogenicity Assessment & Clinical Relevance PART 3B - Regulatory Agencies' Input on Immunogenicity/Technologies of Biotherapeutics, Gene, Cell & Vaccine Therapies)Omar Tounekti, Sophie Shubow, Sarah Wassmer, et al.
Pageof 16